VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Recommendation of “Reduce” by Brokerages

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has earned a consensus recommendation of “Reduce” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $0.95.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Monday, August 31st.

VistaGen Therapeutics Stock Performance

Shares of VTGN stock traded up $0.00 during mid-day trading on Friday, reaching $0.24. The company’s stock had a trading volume of 10,146 shares, compared to its average volume of 1,976,247. The firm’s 50-day moving average is $0.25 and its two-hundred day moving average is $0.46. VistaGen Therapeutics has a 1-year low of $0.20 and a 1-year high of $5.14. The company has a market cap of $10.47 million, a P/E ratio of -0.14 and a beta of 0.39.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. The firm had revenue of $1.48 million during the quarter, compared to analyst estimates of $0.50 million. Sell-side analysts anticipate that VistaGen Therapeutics will post -1.45 EPS for the current year.

Institutional Trading of VistaGen Therapeutics

Several hedge funds have recently modified their holdings of VTGN. ADAR1 Capital Management LLC increased its stake in shares of VistaGen Therapeutics by 49.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 751,141 shares of the company’s stock valued at $429,000 after buying an additional 247,566 shares during the period. BlackRock Inc. acquired a new stake in shares of VistaGen Therapeutics during the 2nd quarter worth approximately $78,000. Renaissance Technologies LLC grew its holdings in VistaGen Therapeutics by 81.2% during the 1st quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock worth $166,000 after acquiring an additional 130,509 shares during the period. AdvisorShares Investments LLC lifted its stake in shares of VistaGen Therapeutics by 10.8% in the 1st quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock valued at $158,000 after purchasing an additional 26,922 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new position in shares of VistaGen Therapeutics in the 4th quarter valued at $42,000. 78.39% of the stock is owned by institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.